Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.
Int J Drug Policy. 2024 Nov;133:104605. doi: 10.1016/j.drugpo.2024.104605. Epub 2024 Oct 10.
Gabapentinoids are among the most widely prescribed pain medications worldwide. However, there is growing evidence of harms associated with their use. The aim of this study was to systematically review and synthesise qualitative research exploring lived experiences of gabapentinoid (pregabalin and/or gabapentin) misuse and symptoms of dependence.
Six databases (MEDLINE, Scopus, Web of Science, CINAHL, EMBASE, PsycINFO) and grey literature sources were searched from inception to September 2023. The methodological quality of included studies was appraised using a modified 11-item version of the Critical Appraisal Skills Programme qualitative checklist, and higher quality studies were prioritised in the thematic synthesis. Confidence in the overall findings of the review was assessed using the GRADE-CERQual approach. The review was prospectively registered on PROSPERO (CRD42023401832).
Twenty-six articles representing 21 original studies were included. The majority used interview methods and were of high methodological quality. Motives for gabapentinoid misuse included getting high, potentiating or offsetting the effects of other drugs, self-medicating for pain, distress, insomnia, or withdrawal symptoms, and substituting for another drug. Symptoms of dependence included the rapid development of tolerance and a severe withdrawal syndrome often involving psychiatric symptoms. Harms including dissociation, loss of consciousness, and overdose were generally reported as a consequence of polysubstance use. Confidence in most of the review findings was moderate with low confidence in one finding.
This review provides rich qualitative insights into the potential motives for gabapentinoid misuse as well as the diverse lived experiences of dependence symptomatology. Considering the increasing prescribing of these medications globally, and the potential for public health challenges resulting from misuse, the findings of this review can be used to develop more effective harm reduction strategies.
加巴喷丁类药物是全球应用最广泛的止痛药物之一。然而,越来越多的证据表明其使用存在危害。本研究旨在系统回顾和综合定性研究,以探索加巴喷丁类药物(普瑞巴林和/或加巴喷丁)滥用和依赖症状的真实体验。
从建库到 2023 年 9 月,我们检索了 6 个数据库(MEDLINE、Scopus、Web of Science、CINAHL、EMBASE、PsycINFO)和灰色文献来源。使用经过改良的 11 项批判性评价技巧方案定性清单评估纳入研究的方法学质量,并在主题综合中优先考虑高质量研究。使用 GRADE-CERQual 方法评估综述总体发现的信心。该综述已在 PROSPERO(CRD42023401832)上进行了前瞻性注册。
共纳入 26 篇文章,代表 21 项原始研究。大多数研究采用访谈方法,方法学质量较高。加巴喷丁类药物滥用的动机包括获得快感、增强或抵消其他药物的作用、自我治疗疼痛、焦虑、失眠或戒断症状,以及替代另一种药物。依赖症状包括快速产生耐受性和严重戒断综合征,常伴有精神症状。分离、失去意识和过量等危害通常被报告为多药滥用的后果。大多数综述发现的信心为中度,有一个发现的信心较低。
本综述提供了丰富的定性见解,了解加巴喷丁类药物滥用的潜在动机以及依赖症状的各种真实体验。考虑到这些药物在全球范围内的处方量不断增加,以及滥用可能带来的公共卫生挑战,本综述的结果可用于制定更有效的减少伤害策略。